Company ProfilePremium

Recce Pharmaceuticals Ltd

Company Profile Analysis

Ticker: RCE.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Recce Pharmaceuticals Ltd - Company showcase

Year Founded & Workforce

2007

Recce Pharmaceuticals Ltd logo

Recce Pharmaceuticals Ltd Employee Contacts

7 verified contactsNames, job titles, seniority and locations

View Employee Contacts

Recce Pharmaceuticals Ltd Overview

Recce Pharmaceuticals is a clinical-stage Australian biotechnology company developing a new class of synthetic polymer anti-infectives aimed at antimicrobial resistance (AMR). Its lead asset, RECCE® 327 (R327), is a broad-spectrum agent active against Gram-positive and Gram-negative bacteria, including resistant "superbug" strains. It is being developed as a topical gel (R327G), an intravenous infusion, and a nebulised inhaled therapy. R327 holds FDA Qualified Infectious Disease Product (QIDP) status with Fast Track designation and appears in the WHO antibacterial clinical pipeline. The near-term thesis rests on R327G in diabetic foot infections (DFI): a registrational, placebo-controlled Phase 3 in Indonesia (up to 310 patients, interim analysis at 155) and a pivotal active-comparator Phase 3 in Australia run to TGA and FDA standards. Recce has no product revenue, owns its manufacturing, and relies heavily on the Australian R&D Tax Incentive, US defence grants, an Avenue Capital debt facility and frequent equity raisings. Governance tensions with shareholders became acute in 2025–26.


Company's own description (FY26 Annual Report, paraphrased)

Recce describes itself as developing a new class of synthetic anti-infectives to tackle antibiotic-resistant superbugs. The pipeline consists of three patented, broad-spectrum synthetic polymer anti-infectives:

RECCE® 327 (R327): intravenous and topical therapy for serious and potentially life-threatening Gram-positive and Gram-negative infections, including resistant forms.

RECCE® 435 (R435): orally administered therapy for bacterial infections.

RECCE® 529 (R529): for viral infections.

The company attributes the platform's potential to overcome resistance to its "multi-layered mechanisms of action." It highlights that the WHO lists R327, R435 and R529 among antibacterial products in clinical development for priority pathogens, and that the FDA has granted R327 QIDP status under the GAIN Act with Fast Track designation. It also notes R327's inclusion in The Pew Charitable Trusts' antibiotic pipeline as the sole synthetic polymer and sepsis candidate, and that Recce wholly owns its automated manufacturing. In the Directors' Report, the principal activity is described as developing and commercialising new classes of synthetic anti-infectives against resistant superbugs and emerging viral pathogens.

Business model and revenue model

DimensionCurrent state (FY2026)Planned / target state
Revenue from ordinary activitiesNil (FY2026 and FY2025)First product revenue targeted after Indonesian approval of R327G (company guidance: approval anticipated in CY2026)
Product vs service vs licensing mix100% pre-revenue. "Other income" consists of the R&D tax incentive, grants and interest.Hybrid: (a) direct or partner-led product sales in Indonesia and ASEAN; (b) out-licensing with Recce as manufacturer and supplier (MENA term sheet: upfront/milestones up to US$3.5m, plus a 30% royalty on net selling price and an additional 6% on annual net sales above US$50m)
Non-dilutive fundingR&D Tax Incentive (A$8.88m recognised in FY26); US defence grant income (A$0.50m in FY26); Canadian SR&ED refund (A$0.27m in FY25)Advanced Overseas Finding of up to A$85m in eligible offshore R&D, eligible for the 43.5% refundable offset over three years
Debt fundingAvenue Venture Opportunity Fund II facility: A$30.55m total, A$11.49m drawn at 30 June 2026Remaining tranches subject to drawdown conditions
Equity fundingPlacements, SPPs and entitlement offers; Acuity Capital at-the-market facility (to 31 January 2031)Ongoing

Value-chain position

Recce is vertically integrated across discovery (its in-house chemistry platform and an Anti-Infective Research Unit at the Murdoch Children's Research Institute in Melbourne), clinical development, and API and finished-product manufacturing (Macquarie Park, Sydney). Commercial distribution is expected to be partnered: PT Etana Biotechnologies is the Indonesian sponsor, and an unnamed Middle Eastern licensee is proposed under a non-binding term sheet. Under that term sheet, Recce would stay the manufacturer and supplier, giving it a manufacturing margin plus royalty. MST Access (February 2026) models a 92% gross margin at launch.

Customer types and end-markets (prospective)

End-marketCustomer typeAssetStage
Diabetic foot infections (mild to moderate)Hospitals, wound-care clinics, podiatry, primary care; government payers (Indonesia, KSA/GCC); licensee distributorsR327G topical gelPhase 3 (Indonesia, Australia)
ABSSSI / acute wound infectionsHospitals, emergency departmentsR327GPhase II completed (Feb 2025); folded into the DFI Phase 3 strategy
Burn wound infections (military and civilian)US Department of War (formerly DoD) and US Army; burn centresR327GPreclinical (two CRADAs, US$2m CDMRP grant)
Complicated UTI / urosepsis / sepsisHospitals (IV)R327 IVPhase I and Phase I/II completed; Phase II planned
HAP/VAP (inhaled)ICU and ventilated patientsNebulised R327Preclinical (MCRI)
Biodefence countermeasuresUS governmentR327In-vitro data (MHSRS 2025)
Viral infections—R529Early research
Oral antibacterial—R435Early research

Independent characterisation

Recce is a single-platform, single-lead-asset, pre-revenue biotech. Its valuation hinges on one binary event: positive Indonesian Phase 3 interim data for R327G, followed by Badan POM approval under expedited review. The platform is genuinely differentiated as a synthetic polymer anti-infective, which most AMR pipelines do not offer, and it carries meaningful external validation (QIDP/Fast Track, WHO and Pew listings, US Army CRADAs). Its clinical evidence, however, rests on open-label Phase II data in 30 patients and first-in-human safety data. Strategically, the company has pivoted from a US/IV-first sepsis story to an emerging-market, topical-first DFI story. That is cheaper and faster, but it targets lower-priced markets where its mechanism claims have not yet been tested in a controlled efficacy setting. The balance sheet is thin: A$2.7m cash and negative equity of about A$16.7m at 30 June 2026. Governance is the most visible non-clinical risk. The founder's family occupies the CEO and CSO roles, the chair is executive, the Board lacks an independent majority, and shareholders have repeatedly voted down remuneration and capital resolutions.

Strategy

Stated strategic themes (FY26 Annual Report, paraphrased; short quotes only)

  1. Late-stage clinical execution: run two registrational Phase 3 DFI trials in parallel, deliver the Indonesian interim readout, and obtain Indonesian approval as the first commercial milestone.

  2. Dual-market regulatory strategy: use the Australian pivotal trial, run to TGA and FDA standards, to support TGA and FDA submissions. AUS/US registration is targeted for 2028, with an FDA IND first.

  3. Partnership-led international expansion: the Chairman frames MENA as part of "capital-efficient, partnership-led market expansion," using the clinical package and designations to license to regional operators.

  4. US Government as a "second pillar": expand the Department of War burn wound programme through the CDMRP grant and the USAMRIID and USAISR CRADAs.

  5. Pipeline breadth through preclinical research: inhaled R327 (HAP/VAP), IV R327 (UTI/urosepsis), and biodefence.

  6. Non-dilutive funding first: R&D Tax Incentive, the A$85m Advanced Overseas Finding, grants and the Avenue debt facility, supplemented by equity.

  7. Scientific credibility: the AR anticipates a peer-reviewed mechanism-of-action paper in CY2026. The September 2026 GM deck lists it as "published".

Strategic initiatives in the last 24 months

DateInitiativeTypeDetail / target
Jul 2024US DoD CDMRP grantGovernment fundingUS$2m for R327G in burn wounds
Dec 2024Indonesian Phase 3 approvalClinical / regulatoryExpedited review; first DFI trial of its kind in Indonesia
Apr 2025USAMRIID CRADAPartnershipDTRA-funded
Jun 2025Avenue debt facilityFinancingUp to US$20m; warrants equal to 8% of the loan amount
Sep 2025Indonesian Phase 3 dosingClinical5 sites; up to 310 patients
Dec 2025Advanced Overseas FindingFundingUp to A$85m of offshore R&D eligible for the 43.5% offset over 3 years
Feb 2026USAISR CRADAPartnershipWalker-Mason burn model
May 2026MENA licence term sheetCommercial10-year exclusive; 12 countries
Jun 2026Australian trial elevated to pivotal Phase 3ClinicalActive comparator; mild and moderate DFI; ulcers below the knee
Jun–Jul 2026Placement and SPPFinancingA$6.4m. Planned use: A$3.2m balance sheet and licensing, A$2.0m trials, A$2.0m IND-enabling work (FDA, BPOM), A$0.8m working capital and costs
Aug 2026HREC approval of comparator studyClinicalPivotal Phase 3 DFI

Sustainability / ESG commitments: none disclosed beyond policies. Cost programmes: none announced; the FY26 cost reduction was implicit.

Guidance and targets (latest disclosures)

ItemGuidanceSourceTrack record
Indonesian interim dataQ3 CY2026 (GM deck, Sep 2026)GM presentationEarlier guidance: Q1 2026 (Biotech Dispatch, Sep 2025; MST Access, Feb 2026). Results "by late 2025" was guided at trial approval in Dec 2024. Repeated slippage; no readout found as of 14 Oct 2026.
Indonesian approval / launchApproval anticipated CY2026; commercialisation 2027Q4 FY26 4C; GM deckJan 2026 presentation targeted availability in Indonesia in 2026; Edison assumed launch in H2 CY2026
MENA definitive agreement"Next quarter" / Q4 CY2026Q4 FY26 4C (internally inconsistent wording)Pending
KSA commercial approvalTargeted "by year end" with expedited review, relying on Indonesian dataQ4 FY26 4CContingent on Indonesian data
Australian Phase 3Full enrolment by end of 2027Q4 FY26 4C18 of about 200 patients treated at 21 Jul 2026
AUS/US registration2,028FY26 AR—
FDA IND for R327GPlanned; MST Access expected H1 CY2026FY26 AR; MSTNot yet announced
Medium-term financial targetsNone published——

Products & Services

No product is approved or marketed. The catalogue below lists every disclosed development product and formulation.

RECCE® 327 Topical Gel (R327G) — flagship

AttributeDetail
DescriptionTopical gel of R327, a synthetic polymer anti-infective with broad-spectrum activity, designed as a next-generation gel wound dressing
Key capabilitiesPhase II ABSSSI (Australia, 30 patients, open label): 93% primary efficacy endpoint over 14 days and 86% clinical response by day 7, with no serious adverse events (FY25 and FY26 ARs). Preclinical burn models: about 3-log reduction of P. aeruginosa by day 4 and 4-log by day 8; about 2-log reduction of MRSA by day 4 and 3-log by day 8. It outperformed Soframycin with once-daily versus twice-daily dosing and accelerated wound contraction (FY26 AR).
IndicationsDFI (mild and moderate, about 80% of DFI presentations per company); ABSSSI; burn wound infections
Target customerHospital and community wound care; government health systems; military field kits
Development statusIndonesian Phase 3: registrational, double-blind, placebo-controlled, 5 sites, up to 310 patients, interim analysis at 155, primary endpoint Lipsky Scale clinical response. Australian Phase 3: pivotal, active-comparator (one of four physician-selected antibiotics), non-inferiority and superiority design, about 200 patients (Q4 FY26 4C; the GM deck says 208), interim at 50%.
Launch timing (guidance)Indonesia approval anticipated in CY2026 (Q4 FY26 4C; FY26 AR). The September 2026 GM deck points to commercialisation in 2027. Australia/US registration targeted for 2028 (FY26 AR).
PricingMENA term sheet proposes US$1,500 per treatment, subject to Saudi regulatory agreement (Q4 FY26 4C). Indonesian pricing not publicly disclosed.
Regulatory designationsFDA QIDP and Fast Track (R327); expedited review status in Indonesia

RECCE® 327 Intravenous (R327 IV)

AttributeDetail
DescriptionIV infusion for serious Gram-positive and Gram-negative infections, including urinary tract infections, urosepsis and sepsis
Key dataPhase I (R327-001, reported 20 Jul 2023): 80 healthy males in 8 cohorts, 50mg to 6,000mg one-hour infusion, no SAEs, linear PK, urine concentrations up to 21x plasma (FY26 AR says up to 20x). Phase I/II: 3,000mg over 30 minutes safe (Sep 2023). Edison notes a 4,000mg 30-minute cohort was cleared. Ex vivo, R327-treated urine eliminated E. coli.
StatusA Phase II UTI/urosepsis trial is planned. MST Access had expected a start in H1 CY2026; no start was confirmed in FY26 filings.
Commercial viewEdison sees the IV formulation as Recce's largest commercial opportunity (sepsis/urosepsis and cUTI). MST Access estimates about A$105m more is needed to bring the IV programmes to commercial readiness.
Pricing—

Inhaled / nebulised R327

AttributeDetail
DescriptionNebulised R327 for hospital- and ventilator-acquired pneumonia
Key dataMCRI model with carbapenem-resistant Acinetobacter baumannii, 40 mice: nebulised R327 produced a 4-log (>99.99%) reduction in lung bacterial burden, approaching the limit of detection, with early signs of lower inflammation. The company notes meropenem cannot be effectively nebulised.
StatusPreclinical; the GM deck lists Phase I/II and registrational trials as future steps

RECCE® 435 (R435)

Oral therapy for bacterial infections; listed on the WHO pipeline. Early-stage. Specifications, timelines and pricing are not publicly disclosed.

RECCE® 529 (R529)

Antiviral candidate; listed on the WHO pipeline. Early-stage. Specifications are not publicly disclosed.

Biodefence application of R327

At MHSRS 2025 (Kissimmee, Florida, 4–7 August 2025), Recce presented in-vitro activity against CDC Category A/B threat pathogens: B. anthracis, F. tularensis, B. mallei, B. pseudomallei and Y. pestis (FY26 AR). There is no clinical programme.

Services

Recce offers no commercial services.

Financial Narrative

Income statement

Sources: FY24–FY26 net loss, R&D incentive and EPS from company Annual Reports and Appendix 4E. FY22–FY25 other income, operating income, EBITDA and interest from StockAnalysis (aggregator), which labels other income as "revenue". FY26 other income of A$9,939,158 from the FY26 report via FilingReader. Total expenses are derived as net loss plus other income. FY22–FY23 EPS is aggregator data rounded to whole cents.

Margins and growth. Gross, operating, EBITDA and net margins are not meaningful with nil revenue, and revenue CAGR is undefined. Other income grew at a 34% CAGR from FY2022 to FY2026 (analyst-derived from 3.08 to 9.94), driven by the rising R&D Tax Incentive as clinical spend scaled.

Commentary. Losses widened every year from FY2022 to FY2025, peaking at A$21.4m as the Phase II ABSSSI trial ran, Phase 3 start-up began, financing costs rose and share-based payments increased. FY2026 is an inflection: the net loss fell 30% to A$14.96m. The company attributes this to lower R&D expenditure. The R&D incentive also rose to A$8.88m, helped by the Advanced Overseas Finding, which lets Indonesian trial spend qualify. Lower R&D spend during a Phase 3 year mainly reflects funding constraints: Q2 FY26 ended with only A$0.4m of cash, per MST Access. It does not signal operating efficiency. Loss per share fell from 9.04c to 5.17c, helped by a larger weighted share count after the FY25 raisings.

Data conflict. StockAnalysis reports a trailing-twelve-month loss to 31 December 2025 of A$30.25m. That figure is inconsistent with the audited H1 and FY26 results and appears to be an aggregator artefact, so it has been disregarded.

Balance sheet

Sources: FY22–FY25 from StockAnalysis (aggregator), cross-checked against Simply Wall St for FY25 (total debt A$10.13m, equity -A$3.05m, assets A$12.41m). FY26 cash of A$2,694,474 and NTA per share from the FY26 Annual Report. FY26 equity of about -A$16.7m and accumulated losses of about A$101m come from shareholder commentary at the 2 September 2026 GM (Mayne Report); this is consistent with NTA of -5.78c across about 289m shares. FY26 Avenue drawn balance from the Q4 FY26 Appendix 4C, Section 7. FY26 net debt is analyst-derived as A$11.49m drawn less A$2.69m cash and excludes leases. Goodwill and intangibles are nil because no capitalised intangibles were identified.

Data conflict. The Q4 FY26 Appendix 4C reports cash at 30 June 2026 of A$2,896,729, while the audited Annual Report gives A$2,694,474. The difference of about A$0.2m is unexplained in the material reviewed.

Commentary. Equity has been negative since FY2023 because accumulated losses outran capital raised and debt-like funding filled the gap: R&D advance loans in FY23–FY24, then the Avenue facility from June 2025. Working capital turned positive in FY2025 only because of the A$15.8m+ equity raise and the reclassification of debt to long-term. At 30 June 2026 the company held A$3.94m of placement proceeds as "equity pending allotment"; the shares were allotted on 1 July 2026.

Cash flow

Source: StockAnalysis (aggregator). Cross-check: FY25 cash of A$10.45m less A$7.75m gives A$2.70m, matching the audited FY26 cash of A$2.69m. The Q4 FY26 Appendix 4C gives FY26 net operating cash outflow of A$10.02m (aggregator: A$9.89m). The aggregator's FY25 equity issuance of A$28.35m exceeds the A$15.8m the company cites for FY25. The likely explanation is that the July–August 2024 A$8m placement and SPP also fell in FY25, but the variance is unreconciled.

FY2026 operating cash outflow by category (Q4 FY26 Appendix 4C, AUD)

Commentary. Cash burn roughly halved in FY2026, from A$20.4m to about A$10m. That came from both A$5.8m of tax incentive receipts and reduced trial spend. Q4 FY26 operating outflow was A$2.17m, and the company's Appendix 4C estimated 10.87 quarters of funding based on A$23.6m of "available funding", which includes A$20.7m of undrawn Avenue facility subject to conditions. On cash alone, runway at 30 June 2026 was about one quarter before the July 2026 inflows: the A$3.67m tax refund and the A$2.4m SPP.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Entity / Unit Details

Entity / unitFunctionDisclosure status

Recce Pharmaceuticals Ltd (parent)

Listed holding entity; R&D sponsor; IP owner

FY26 AR

Controlled entities

The AR refers to "controlled entities" (the Group). Names were not captured in this research.

Not publicly disclosed in material reviewed

Macquarie Park manufacturing

API and finished-product manufacture (GMP)

Company releases

Anti-Infective Research Unit at MCRI (Melbourne)

Preclinical research (e.g., HAP/VAP models)

FY26 AR

Outsourced finance function

CFO Justin Reynolds is a partner at Pitcher Partners Sydney (outsourced)

FY26 AR

Outsourced company secretarial

Maggie Niewidok, Kardos Scanlan Corporate Lawyers

FY26 AR

Results by Segment

MetricFY2024FY2025FY2026

Segment revenue – Anti-infectives R&D (AUD Mn)

000

Segment net loss – Anti-infectives R&D (AUD Mn)

-17.66-21.43-14.96

Contribution to total revenue (%)

000

Capital Programmes

ProgrammeContentsFY2026 status

R327 Topical (R327G)

DFI Phase 3 (Indonesia, Australia); ABSSSI Phase II complete; burn wound (US)

Lead value driver

R327 Intravenous

UTI/urosepsis, sepsis

Phase I and I/II complete; Phase II planned

R327 Inhaled

HAP/VAP nebulised

Preclinical

R435

Oral antibacterial

Early research

R529

Antiviral

Early research

Government / biodefence

US Department of War burn wound programme; bioterrorism pathogens

Preclinical / in vitro

Income Statement and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Revenue from ordinary activities (AUD Mn)

00000

Other income incl. R&D tax incentive, grants, interest (AUD Mn)

3.084.375.037.519.94

of which R&D Tax Incentive recognised (AUD Mn)

——4.916.748.88

of which US defence grant income (AUD Mn)

————0.50

Total expenses, analyst-derived (AUD Mn)

14.0717.4522.6928.9424.90

Gross profit (AUD Mn)

00000

Operating income, aggregator (AUD Mn)

-9.65-12.88-17.00-20.41—

EBITDA, aggregator (AUD Mn)

-9.60-12.83-16.93-20.33—

Interest expense, aggregator (AUD Mn)

0.010.180.841.21—

Pre-tax income (AUD Mn)

-10.99-13.08-17.66-21.43-14.96

Net income (AUD Mn)

-10.99-13.08-17.66-21.43-14.96

EPS basic and diluted (AUD cents)

-6-8-9.97-9.04-5.17

Dividends per share (AUD)

00000

Balance Sheet and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Cash and equivalents (AUD Mn)

11.581.564.4210.452.69

Total current assets (AUD Mn)

12.181.955.1411.39—

PP&E (AUD Mn)

0.440.611.231.03—

Total assets (AUD Mn)

12.622.566.3712.41—

Current liabilities (AUD Mn)

2.454.8515.076.13—

Total debt incl. leases (AUD Mn)

0.073.3010.5010.77—

Short-term debt (AUD Mn)

03.059.691.53—

Long-term debt (AUD Mn)

0008.60—

Avenue loan facility drawn (AUD Mn)

————11.49

Net debt, analyst-derived (AUD Mn)

-11.511.746.080.328.80

Total liabilities (AUD Mn)

2.565.1415.8915.47—

Shareholders' equity (AUD Mn)

10.06-2.59-9.52-3.05-16.7

Goodwill and intangibles (AUD Mn)

00000

Working capital (AUD Mn)

9.74-2.90-9.935.26—

NTA per share (AUD cents)

———-1.06-5.78

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Operating cash flow (AUD Mn)

-9.01-12.69-13.01-20.44-9.89

Capital expenditure (AUD Mn)

-0.04-0.04-0.14-0.03-0.06

Free cash flow (AUD Mn)

-9.05-12.73-13.15-20.47-9.95

Equity issued (AUD Mn)

0.290.1011.1528.353.94

Debt issued (AUD Mn)

02.8810.0912.220.06

Debt repaid (AUD Mn)

-0.14-0.17-4.51-11.92-1.71

Financing cash flow (AUD Mn)

-0.242.7116.1726.922.01

Dividends paid (AUD Mn)

00000

Share buybacks (AUD Mn)

00000

Net change in cash (AUD Mn)

-9.29-10.022.856.03-7.75

Financial Analysis

CategoryYear to date FY2026

Research and development

-11,659,449

Staff costs

-2,780,924

Administration and corporate

-1,400,334

Advertising and marketing

-483,320

Government grants and tax incentives received

5,807,722

Net operating cash flow

-10,024,008

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025

ROA (%)

-87-511-277-173

Current ratio (x)

4.970.400.341.86

Debt to equity (x)

0.01-1.27-1.10-3.53

Ratio

Assessment

———

ROE

Not meaningful; equity negative from FY2023

———

ROIC

Not meaningful; negative invested capital and operating losses

———

Net debt / EBITDA

Not meaningful; EBITDA negative

———

Interest coverage

Not meaningful; operating losses. Aggregator FY25 interest expense was A$1.21m.

———

Asset turnover

Zero; no revenue

———

Cash conversion cycle

Not applicable; no trade receivables or inventory cycle

———

Results by Region

MetricFY2024FY2025FY2026

Revenue – Australia (AUD Mn)

000

Revenue – Asia ex-Australia (AUD Mn)

000

Revenue – Americas (AUD Mn)

000

Revenue – EMEA (AUD Mn)

000

Other income – Australia, R&D Tax Incentive (AUD Mn)

4.916.748.88

Other income – USA, defence grant (AUD Mn)

——0.50

Other income – Canada, SR&ED refund (AUD Mn)

—0.27—

Region Overview

RegionRoleStatus

Indonesia

First commercial market; registrational Phase 3

Approval anticipated CY2026

ASEAN (Malaysia, Thailand, Singapore, Philippines)

Follow-on approvals; company cites about a US$1.5bn opportunity

Post-Indonesia

MENA (12 countries per AR; the 4C names KSA, UAE, Kuwait, Oman, Bahrain, Qatar, Egypt, Algeria, Morocco)

Out-licensed distribution

Non-binding term sheet; definitive agreement guided for "next quarter" / Q4 CY2026

Australia

Pivotal Phase 3; TGA filing

Registration targeted 2028

United States

FDA IND, then NDA; DoD/Department of War burn programme

IND planned; registration targeted 2028

Brazil, China, Japan, Canada, Israel, Hong Kong, Vietnam

Patent coverage

No development activity disclosed

Share Price History

DatePrice (AUD)Source

Jan 2016 (IPO)

0.20

Biotech Daily

9 Oct 2020 (option grant date)

1.115

FY26 AR

30 Jun 2025

0.29

Market Index

10 Feb 2026

0.58

MST Access

4 Apr 2026

0.47

Edison

24 Jul 2026

0.36

StockAnalysis

1 Sep 2026

0.36

InvestSMART

22 Sep 2026

0.325

StockAnalysis

29 Sep 2026

0.32

Google Finance

Metric

FY2025

FY2026

Fiscal year-end share price (AUD)

0.29—

Performance metric

Value

Source

52-week range

A$0.31 – A$0.73

Google Finance (29 Sep 2026)

5-year high

A$1.38

MarketScreener

10-year high

A$1.88

MarketScreener

1-year relative performance

-22.6% vs sector; -35.0% vs ASX 200

Market Index

Absolute 1-, 3- and 5-year total return

Price data points imply a steep 5-year decline from above A$1.00 in late 2020 to A$0.32.

—

Beta (5-year)

0.39

StockAnalysis

Valuation Multiples

MultipleRecceComment

Market cap

About A$99.4m

Google Finance

Enterprise value

About A$108m (A$99.4m plus about A$8.8m net debt at 30 Jun 2026)

Analyst-derived; StockAnalysis gave EV of A$108.25m on 24 Jul 2026

P/E

n.m. (loss-making); MarketScreener consensus P/E of -6.8x for 2026

Aggregator

EV/Sales

n.m. (nil revenue); aggregator quotes are based on other income

—

P/B

Negative (equity about -A$16.7m)

—

Firm Details

FirmTypeView

MST Access

Company-sponsored

A$764m valuation, A$2.40 per share (A$2.17 fully diluted); rNPV at a 12.5% discount rate; 10 Feb 2026

Edison Investment Research

Company-sponsored

rNPV at a 12.5% discount rate across four programmes; per-share value not captured in this research

Consensus

Simply Wall St reports 2 analysts contributing estimates

Consensus targets not publicly disclosed

Capital Markets

ItemStatus

Dividend history and policy

No dividend has ever been paid or declared (FY26 Appendix 4E)

Buybacks

None authorised

Credit ratings (Moody's, S&P, Fitch)

None; unrated

Debt maturity profile

Avenue facility: A$30.55m total, A$11.49m drawn at 30 Jun 2026. Interest rate and amortisation schedule not captured in this research. Warrants exercisable for 5 years from execution. Aggregator FY25 split: A$1.53m current and A$8.60m non-current.

Equity overhang

Avenue warrant (up to 4.63m shares); Acuity ATM (about 4.5m shares); unlisted options; MST counted 32.9m options and performance rights in Feb 2026

Capital raised FY2025–FY2026

A$22.2m of equity in total (A$15.8m in FY25 plus A$6.4m in FY26, per the CEO letter)

Analyst Conclusions

Management guidance (latest)

  • Indonesian Phase 3 interim readout guided for Q3 CY2026; no readout had been found as of 14 October 2026, so the guidance window has passed.

  • Indonesian regulatory approval anticipated in CY2026, with commercialisation in 2027.

  • Definitive MENA licence agreement guided for Q4 CY2026; KSA approval targeted to rely on Indonesian data.

  • Australian pivotal Phase 3 fully enrolled by end-2027; AUS/US registration targeted for 2028.

  • An FDA IND, a Phase II IV UTI/urosepsis trial, and a peer-reviewed mechanism-of-action publication are all planned.

  • No revenue or earnings guidance has been issued. No consensus revenue estimates were verified.

Bull case

  1. Binary upside from a low base. At about A$99m market cap, positive interim data on the placebo-controlled Indonesian trial, with the protocol designed to show significance at about 155 patients, could trigger approval under expedited review, a definitive MENA deal and ASEAN filings. MST's sponsored A$2.40 per share valuation shows the theoretical gap.

  2. Validated, differentiated platform. QIDP and Fast Track, the WHO and Pew listings, two US Army CRADAs and a clean Badan POM inspection all support the platform. One molecule spans topical, IV and inhaled markets, including Edison's preferred IV sepsis and cUTI franchise.

  3. Non-dilutive leverage. The A$85m Advanced Overseas Finding makes Indonesian trial spend eligible for a 43.5% cash refund. The FY26 incentive of A$8.88m offset about 59% of the loss, and undrawn Avenue debt of A$20.7m could fund the path to launch if conditions are met.

Bear case

  1. Credibility of timelines and evidence. The interim readout has slipped at least three times (late 2025, Q1 2026, Q3 2026). Efficacy evidence remains a 30-patient open-label Phase II, and topical DFI has a history of Phase 3 failure.

  2. Balance-sheet fragility and dilution. Cash was A$2.69m and equity about -A$16.7m at 30 June 2026, and debt drawdowns are conditional. The SPP raised only 60% of its target, and shareholders blocked option sweeteners, constraining future capital-raising tools.

  3. Governance overhang. Successive remuneration strikes, the 2 September 2026 defeat of all resolutions, and the s249N director nominations point to a possible board contest at the 2026 AGM. Family control of executive roles, related-party consulting and an executive chair compound the discount.

Key catalysts and monitorables (next 12 months)

CatalystExpected timingWhy it matters
Indonesian Phase 3 interim analysis (155 patients)Overdue against Q3 CY2026 guidanceThe single most important value driver
2026 AGM outcome, including s249N resolutions and board nominationsQ4 CY2026 (per 6 Oct 2026 notice)Board composition, strategy continuity, capital access
Definitive MENA licenceQ4 CY2026 (guided)First upfront cash and commercial validation
Badan POM marketing authorisationCY2026 to 2027First revenue
Q1 FY27 Appendix 4CLate Oct 2026Cash runway and drawn debt
FY2026 R&D Tax Incentive refundH2 CY2026 to H1 CY2027Large non-dilutive inflow (A$8.88m recognised)
Avenue tranche drawdownsEvent-drivenLiquidity; covenant headroom
FDA IND submission2026–2027US pathway credibility
Australian Phase 3 enrolment paceOngoing (18 patients at Jul 2026)Determines TGA/FDA timing
USAISR burn model results2026–2027US defence procurement potential

Analyst verdict

Recce Pharmaceuticals is a high-risk, event-driven proposition whose investment case has narrowed to one question: will R327G show a statistically significant clinical response over placebo in Indonesian diabetic foot infections? Everything else depends on that answer, including MENA royalties, ASEAN expansion, the Saudi approval path and the credibility of the wider polymer platform. The scientific narrative is unusually rich for a company of about A$100m market capitalisation. A genuinely novel synthetic class, FDA QIDP and Fast Track status, WHO and Pew pipeline recognition, two US Army research agreements and a clean regulatory inspection add up to a substantive platform, not a story stock. The FY2026 numbers also show improved cost discipline: the net loss fell 30% to A$14.96m and operating cash burn halved to about A$10m, aided by an A$85m Advanced Overseas Finding that turns offshore trial spend into refundable tax credits.

Against that, the balance sheet is precarious and governance is a live, escalating risk. At 30 June 2026 the company held A$2.7m of cash against about A$11.5m of drawn venture debt and negative equity near A$16.7m, and it depends on conditional debt tranches and tax refunds. Shareholders have now rejected remuneration and capital resolutions at consecutive meetings and lodged s249N director nominations. Management's repeated slippage on the interim readout erodes the guidance credibility that a binary-event stock needs.

Verdict: speculative; event-driven. Risk-tolerant investors with a clear view on topical anti-infective efficacy may find the asymmetry attractive at about A$0.32 per share. Institutional capital should wait for three things: (1) the Indonesian interim readout with full statistics, (2) resolution of the 2026 AGM board contest, and (3) a definitive, funded MENA agreement. Until then, the dominant risks are dilution and governance rather than science.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameRoleAppointedIndependentEducationPrior roles / other boards

Dr John Prendergast

Executive Chairman (US-based)

23 Apr 2018

No

BSc (Hons), MSc and PhD (UNSW); CSS Admin & Mgmt (Harvard)

Co-founder and Chairman, Palatin Technologies (NYSE: PTN); Executive Chairman, Angis Bio; former Lead Director, Nighthawk Biosciences / Heat Biologics; co-founder of Avigen, AVAX, MediciNova; former MD, The Castle Group. Cited as responsible for three NDA approvals.

James Graham

Managing Director and CEO

Director 23 Jun 2015; CEO 28 Aug 2020

No

BCom (Entrepreneurship), GAICD

Marketing, business development and commercialisation background. Reported to be Dr Melrose's grandson (Biotech Daily; Business News Australia).

Michele Dilizia

Executive Director and Chief Scientific Officer

26 Jun 2015

No

BSc (Med Sci), Grad Dip Bus (Mkting), BA (Journ), GAICD, MASM

Co-inventor; medical scientist (microbiology and regulatory affairs); earlier career in PR and marketing. Reported to be Dr Melrose's daughter (Biotech Daily).

Dr Justin Ward

Executive Director and Head of Chemistry / Principal Quality Chemist

8 Jul 2019

No

BSc (Chem), PhD (Chem), MPharm, MRACI, CChem

Pfizer (regulatory data); Laboratory Manager, Solbec; Quality Manager, Phebra

Dr Alan Dunton

Non-Executive Director and Chief Medical Officer/Adviser (US-based)

14 Jul 2020

Yes (per company)

MD (NYU); BS Biochemistry (SUNY Buffalo)

President and MD, Janssen Research Foundation (J&J); CEO of Panacos and Metaphore; COO, Emisphere; boards of Palatin, Oragenics, CorMedix. Cited as responsible for about 20 NDA approvals.

Alistair McKeough

Non-Executive Director

1 Sep 2022

Yes

BA, LLB, LLM

Solicitor; former Recce Company Secretary (from 2017); Automic Group leadership; director of Tissue Repair Ltd (ASX: TRP)

Executive Leadership Team — Arthur Kollaras

NameRoleNotes

Arthur Kollaras

Principal Engineer and Head of Manufacturing (KMP)

Chemical engineer and microbiologist; consultancy since 1 Oct 2021 at A$400 per hour

Justin Reynolds

Chief Financial Officer (outsourced)

Partner, Pitcher Partners Sydney

Maggie Niewidok

Company Secretary

Kardos Scanlan Corporate Lawyers

Directors' Remuneration

NameCash salary and feesLong service leaveSuperannuationBonusShare-based paymentsTotal FY2026Total FY2025

James Graham

660,70732,10330,0000216,450939,2601,292,191

John Prendergast

368,730000202,722571,452758,025

Michele Dilizia

361,10917,15230,0000115,440523,701454,447

Justin Ward

280,0007,66133,600072,150393,411366,290

Alan Dunton

75,000000172,123247,123389,891

Alistair McKeough

81,25000076,499157,749221,201

Arthur Kollaras

525,92010,20563,110043,104642,339745,804

Total KMP

2,352,716

67,121

156,710

0

898,488

3,475,034

4,227,849

Directors' Remuneration by Feature

FeatureStatus

Board size

6 directors: 4 executive, 2 independent non-executive

Independent majority

No. ASX Recommendation 2.4 not met.

Chair independence / CEO separation

Chair is executive and not independent (Rec 2.5 not met). Chair and CEO roles are held by different people.

Audit and Risk Management Committee

Chair: McKeough. Members: Dunton, Prendergast (executive). Met 4 times in FY26. Rec 4.1 not met because a member is executive.

Nomination and Remuneration Committee

Chair: Dunton. Members: McKeough, Prendergast. Met 5 times.

Board meetings FY26

5 (full attendance except McKeough, 4 of 5)

Gender

Board: 5 men, 1 woman. Senior executives: 62% men, 38% women.

Family relationships

CEO and CSO are reported to be the founder's grandson and daughter (Biotech Daily, 2019)

Major Shareholders

HolderShares%

Gavin William Brown

40,195,98113.15

Graham John Hamilton Melrose and Olga Mary Melrose (estate / joint holding)

28,353,3119.27

HSBC Custody Nominees (Australia) Ltd

24,563,9348.03

Buttonwood Nominees Pty Ltd

10,765,7143.52

Think Pink Pty Ltd (Rainbow A/C)

9,075,0002.97

Holders 6–10

Not captured in this research

—

James Graham (indirect)

6,801,0763,000,000

Michele Dilizia

2,724,9371,600,000

John Prendergast

357,9552,650,000

Justin Ward

351,6841,000,000

Alan Dunton (direct and indirect)

146,2882,250,000

Alistair McKeough (indirect)

30,2872,125,000

Arthur Kollaras

107,514700,000

Major Shareholders — G.J.H. and O.M. Melrose

Holder%

G.J.H. and O.M. Melrose

22.11 (stale notice; the register shows 9.27% in one account. Other related accounts may exist, and Mayne Report commentary cites about 13%.)

Gavin William Brown

13.68

FIL Limited (Fidelity International)

8.57

Board & Management Changes

DateEvent

Nov 2024 AGM

Remuneration report second strike (74.41% For, below the 75% threshold). Spill resolution not passed.

14 Nov 2025

Death of founder and major shareholder Dr Melrose

Nov 2025 AGM

Remuneration report receives 19.32% For (first strike of a new cycle). About 25.6% vote against the chair's re-election; three capital resolutions fail (Mayne Report).

2 Sep 2026 GM

All six resolutions fail on poll despite strong proxy support (overall For: 19%–46%). Defeated items include piggyback options for SPP participants and for four directors, and ratification of the June 2026 placement.

29 Sep 2026

Section 249N shareholder notice proposing resolutions and nominating directors for the 2026 AGM. The requisitioning shareholder's identity and the resolutions' content were not captured in this research.

6 Oct 2026

Notice of 2026 AGM issued; meeting date not captured in this research

Competitive Landscape

Competitors by Segment

SegmentCompetitor / productTypePositioning versus Recce

DFI / ABSSSI (topical and systemic standard of care)

Generic antibiotics (amoxicillin-clavulanate, cephalexin, clindamycin, doxycycline, linezolid)

Incumbent standard of care

Cheap and entrenched. Recce's Australian Phase 3 compares directly against four physician-selected antibiotics.

DFI / topical

Microbion Corp (pravibismane)

Private clinical-stage

Direct topical DFI competitor

DFI / topical (historical)

Pexiganan (Dipexium / Locilex)

Failed Phase 3

Shows the regulatory difficulty of topical DFI claims

ABSSSI (systemic)

Basilea (Zevtera / ceftobiprole); Melinta (Baxdela, Orbactiv, Kimyrsa); Paratek (Nuzyra)

Commercial

Approved ABSSSI drugs with QIDP pathways

cUTI / urosepsis (IV R327)

Shionogi (Fetroja / cefiderocol); Venatorx/Menarini (cefepime-taniborbactam); Iterum (Orlynvah / oral sulopenem); Spero/GSK (tebipenem HBr)

Commercial / late-stage

Strong Gram-negative competitors with deeper evidence

HAP/VAP (inhaled R327)

Innoviva Specialty Therapeutics (Xacduro); Shionogi (cefiderocol); inhaled amikacin and tobramycin

Commercial

Systemic standard of care. Recce's angle is a nebulisable broad-spectrum agent.

Novel-class AMR

BioVersys (SIX-listed; alpibectir, BV100); Bugworks; Armata Pharmaceuticals (phage)

Clinical-stage

Compete for AMR "new class" capital and pull incentives

Burn wound infection

Silver sulfadiazine, mafenide, Soframycin (framycetin)

Generic standard of care

Recce's preclinical data claims superiority to Soframycin

Peer Comparison FY2026

MetricRecce PharmaceuticalsIterum Therapeutics

Stage

Phase 3 (pre-revenue)

Commercial (oral sulopenem approved US Oct 2024)

Revenue, latest FY

Nil (FY2026)

—

Net margin

n.m. (loss of A$14.96m)

—

R&D intensity

n.m. (R&D cash A$11.66m in FY26)

—

Company Snapshot

2007

Founded

Sydney, Australia

Headquarters

SWOT Analysis

Strengths

  • Regulatory recognition: FDA QIDP and Fast Track for R327; WHO pipeline listing for R327, R435 and R529; Pew pipeline listing (FY26 AR)
  • Clean safety profile to date: Phase I: 80 subjects up to 6,000mg with no SAEs (Jul 2023). Phase II ABSSSI: no SAEs (Feb 2025).
  • Encouraging Phase II efficacy: 93% primary efficacy endpoint at day 14; 86% clinical response at day 7 (FY25/FY26 AR)
  • Data-integrity validation: Badan POM GCP inspection with no findings blocking the trial (21 Apr 2026)
  • Owned manufacturing: Macquarie Park GMP plant since 2017; Recce would supply MENA licensee
  • Strong IP runway: More than 40 patents and applications; Family 4 expiry 2041 in 8+ jurisdictions (FY26 AR)
  • Non-dilutive support: A$85m Advanced Overseas Finding; R&D incentive of A$8.88m in FY26; US$2m CDMRP grant

Weaknesses

  • Thin liquidity: Cash A$2.69m at 30 Jun 2026; A$0.4m at 31 Dec 2025 (MST Access)
  • Negative equity: About -A$16.7m at 30 Jun 2026; NTA -5.78c per share (FY26 AR)
  • Controlled data not yet generated: Phase II was open-label with 30 patients; the Phase 3 interim has slipped from late 2025 to Q1 2026 to Q3 2026
  • Governance structure: 4 of 6 directors are executive; executive chair; the CEO and CSO are reported to be the founder's family; ASX Recommendations 2.4, 2.5 and 4.1 are not met
  • Related-party payments: A$888,987 to an entity associated with "independent" director Dunton in FY26
  • Small, outsourced finance function: Outsourced CFO; no internal audit (FY26 CGS)

Opportunities

  • First commercial approval: Indonesian approval anticipated CY2026; 20.9m adults with diabetes in Indonesia
  • MENA licence: Term sheet: up to US$3.5m upfront and milestones, 30% royalty, proposed price of US$1,500 per treatment
  • ASEAN roll-out: About a US$1.5bn opportunity cited (FY26 AR)
  • US defence procurement: Two CRADAs; burn wound and biodefence data
  • IV and inhaled franchises: Edison views IV sepsis and cUTI as the strongest commercial opportunity; inhaled R327 shows a 4-log reduction in CRAB pneumonia
  • Expanded DFI label population: HREC-approved inclusion of moderate DFI (about 80% of presentations)

Threats

  • Binary clinical risk: Topical DFI precedent: pexiganan Phase 3 failure; placebo-controlled design in Indonesia
  • Financing and dilution: SPP raised only about A$2.4m of a A$4.0m target; Avenue warrants; ATM facility; FY25 equity raise at A$0.28
  • Shareholder revolt: Sept 2026 GM defeated 6 of 6 resolutions; s249N director nominations (29 Sep 2026)
  • Debt covenants and conditions: A$20.7m of the Avenue facility is undrawn and subject to drawdown conditions
  • Policy dependence: The Directors' Report flags R&D grant continuity and possible repayment on audit
  • Key-person risk: Founder deceased (Nov 2025); concentrated family management

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
17 Apr 2025A$5.0m placement settled (about 17.9m shares at A$0.28)Funding for the Phase 3 start; deep-discount pricing
22 Apr 2025HREC approval to enrol up to 20 more DFI patients in the Australian Phase IIExpands the DFI dataset
28 Apr 2025CRADA with USAMRIID (DTRA-funded)US biodefence validation
5 May 2025Canadian SR&ED refund of A$271,987Minor non-dilutive inflow
16 May 20251-for-6 entitlement offer at A$0.28 completes, raising about A$3.4mRetail participation
26 May 2025China notice of acceptance for Patent Family 4IP in a large market
3 Jun 2025Firm commitments for entitlement shortfallCompletes the A$15.8m programme
17 Jun 2025Avenue Capital debt facility, up to A$30mNon-dilutive, but adds leverage and warrants
30 Jul 2025Warrant issued to Avenue over up to 4,634,303 sharesDilution overhang
5 Aug 2025MHSRS 2025 abstract on biodefence pathogensUS military profile
12 Aug 2025Positive burn wound rat data versus SoframycinSupports the DoW programme
29 Aug 2025FY2025 Annual Report: loss of A$21.4mPeak loss year
25 Sep 2025Indonesian registrational Phase 3: dosing underway at 5 sitesKey de-risking event
7 Oct 2025Cancellation of securities held by Dilizia and GrahamOption lapses
Nov 2025AGM: remuneration report 19.32% For (first strike); chair re-election about 25.6% against; three capital resolutions failEscalating shareholder dissent
14 Nov 2025Death of founder Dr Graham MelroseLarge estate holding creates register uncertainty
26 Nov 2025MCRI data: nebulised R327 4-log reduction in a CRAB pneumonia modelInhaled pipeline
27 Nov 2025Hong Kong Family 4 patent granted (expiry 2041)IP
16 Dec 2025Advanced Overseas Finding of up to A$85mMajor non-dilutive enabler
5 Jan 2026Investor presentation: goal of product availability in Indonesia in 2026Commercial timeline marker
14 Jan 2026A$5.3m R&D tax refund received (FY25)Liquidity relief; cash had been A$0.4m at 31 Dec 2025
2 Feb 2026Second CRADA, with USAISRDeepens the US relationship
10 Feb 2026MST Access valuation of A$2.40 per share (sponsored); price A$0.58Third-party valuation
27 Feb 2026Half-year report releasedInterim financials
19 Mar 2026KOL investor webinarInvestor engagement
24 Mar 2026Brazil Family 4 patentIP in LatAm
21 Apr 2026Badan POM GCP inspection with no blocking findingsData-integrity de-risking
27 May 2026MENA licence term sheet; further details released the same dayFirst commercial deal (non-binding)
22 Jun 2026HREC approves pivotal Phase 3 in AustraliaPath to TGA and FDA
24 Jun 2026ASX pause in trading pending announcementPrecedes capital raise
26 Jun 2026A$4.0m placement at A$0.40 plus SPPFunding; pro-forma cash about A$29.5m–33.1m including undrawn debt
1–2 Jul 2026A$3.67m R&D tax refund received; 9.85m placement shares allottedLiquidity
14 Jul 2026Vietnam patent grantedIP
21 Jul 2026Q4 FY26 4C: cash A$2.9m; 10.87 quarters of funding including facilitiesFunding visibility
24–31 Jul 2026SPP closes; raises about A$2.4m (about 170 of about 4,400 holders) against a A$4.0m targetWeak retail demand
19 Aug 2026HREC approves comparator study for the pivotal Phase 3 DFI trialProtocol finalised
31 Aug 2026FY2026 Annual Report: loss of A$14.96m; cash A$2.69mResults
2 Sep 2026General Meeting: all six resolutions defeatedMajor governance setback; options for SPP holders blocked
18 Sep 20262026 AGM announced; director nominations window openedGovernance
29 Sep 2026Shareholder s249N notice proposing resolutions and director nominationsPotential board contest
1 Oct 2026Cessation of options (conditions not met)Capital structure
6 Oct 2026Notice of AGM and proxy formUpcoming vote

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

2 charts
Results by Segment: Segment net loss – Anti-infectives R&D rose from AUD -17.7 Mn in FY2024 to AUD -15 Mn in FY2026.
Recce Pharmaceuticals Ltd — Results by Segment
Series (AUD Mn)FY2024FY2025FY2026
Segment net loss – Anti-infectives R&D-17.7-21.4-15

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Recce Pharmaceuticals, Appendix 4E and FY2026 Annual Report (31 Aug 2026)
  2. Recce Pharmaceuticals, FY2025 Annual Report (29 Aug 2025)
  3. Recce Pharmaceuticals, Half-Year Report (27 Feb 2026)
  4. Recce Pharmaceuticals, Q4 FY2026 Quarterly Activities / Appendix 4C (21 Jul 2026)
  5. Recce Pharmaceuticals, General Meeting Presentation (2 Sep 2026)
  6. Recce Pharmaceuticals, Results of General Meeting (2 Sep 2026)
  7. Recce Pharmaceuticals, Investor Presentation (Jan 2026)
  8. Recce Pharmaceuticals, Badan POM Phase 3 approval (9 Dec 2024)
  9. MST Access, "Eyes on Indonesian Phase 3 Trial" (Feb 2026)
  10. Edison Investment Research, Recce coverage · edisongroup.com
  11. ASX filing index (financialfilings.com)
  12. FilingReader (FY26 results: MENA term sheet · June 2026 raise) · filingreader.com · filingreader.com
  13. Kalkine Media (SPP completion, 31 Jul 2026)
  14. Kalkine (trading pause, 24 Jun 2026)
  15. The Mayne Report (2 Sep 2026 EGM commentary)
  16. Market Index (shareholders, substantial holders, auditor, registry)
  17. InvestSMART (announcements, directors' trades)
  18. StockAnalysis (historical financials, statistics, price history)
  19. Simply Wall St (balance sheet health)
  20. MarketScreener (valuation, price extremes)
  21. Google Finance (price, 29 Sep 2026)
  22. Biotech Daily (corporate history, Oct 2019)
  23. BioSpace (Macquarie Park facility, 2017: Phase I/II dosing, 2023) · biospace.com
  24. Patsnap Synapse (Phase I results, 20 Jul 2023)
  25. BioSpectrum Asia (Etana MoU, 8 Feb 2024)
  26. Stockhead (Avenue facility: Indonesian approval) · stockhead.com.au
  27. Biotech Dispatch (Phase 3 dosing: Indonesian inspection) · biotechdispatch.com.au
  28. Business News Australia (A$11m raise; ownership history)
  29. TipRanks (May 2025 entitlement offer)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.